361 related articles for article (PubMed ID: 27750195)
1. An HPLC method associated with a thermodynamic analysis to compare the binding of TRAIL and its nanovectorized form to death receptors DR4 and DR5 and their relationship to cytotoxicity.
Guillaume YC; Lethier L; André C
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Nov; 1036-1037():142-148. PubMed ID: 27750195
[TBL] [Abstract][Full Text] [Related]
2. Comparative binding to DR4 and DR5 receptors of TRAIL and BNNTs/PAHE/mPEG-DSPE/TRAIL nanoparticles.
Guillaume YC; André C
J Mol Recognit; 2017 Jul; 30(7):. PubMed ID: 28120533
[TBL] [Abstract][Full Text] [Related]
3. Enhanced DR5 binding capacity of nanovectorized TRAIL compared to its cytotoxic version by affinity chromatography and molecular docking studies.
Zakaria A; Picaud F; Guillaume YC; Gharbi T; Micheau O; Herlem G
J Mol Recognit; 2016 Sep; 29(9):406-14. PubMed ID: 26952193
[TBL] [Abstract][Full Text] [Related]
4. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.
Tur V; van der Sloot AM; Reis CR; Szegezdi E; Cool RH; Samali A; Serrano L; Quax WJ
J Biol Chem; 2008 Jul; 283(29):20560-8. PubMed ID: 18474604
[TBL] [Abstract][Full Text] [Related]
5. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor.
Truneh A; Sharma S; Silverman C; Khandekar S; Reddy MP; Deen KC; McLaughlin MM; Srinivasula SM; Livi GP; Marshall LA; Alnemri ES; Williams WV; Doyle ML
J Biol Chem; 2000 Jul; 275(30):23319-25. PubMed ID: 10770955
[TBL] [Abstract][Full Text] [Related]
6. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
[TBL] [Abstract][Full Text] [Related]
7. Pro-survival effects by NF-κB, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.
Yang J; Li G; Zhang K
Biomed Pharmacother; 2016 Dec; 84():1078-1087. PubMed ID: 27780136
[TBL] [Abstract][Full Text] [Related]
8. The structure of the death receptor 4-TNF-related apoptosis-inducing ligand (DR4-TRAIL) complex.
Ramamurthy V; Yamniuk AP; Lawrence EJ; Yong W; Schneeweis LA; Cheng L; Murdock M; Corbett MJ; Doyle ML; Sheriff S
Acta Crystallogr F Struct Biol Commun; 2015 Oct; 71(Pt 10):1273-81. PubMed ID: 26457518
[TBL] [Abstract][Full Text] [Related]
9. The enhanced expression of death receptor 5 (DR5) mediated by HBV X protein through NF-kappaB pathway is associated with cell apoptosis induced by (TNF-α related apoptosis inducing ligand) TRAIL in hepatoma cells.
Kong F; You H; Zhao J; Liu W; Hu L; Luo W; Hu W; Tang R; Zheng K
Virol J; 2015 Nov; 12():192. PubMed ID: 26577955
[TBL] [Abstract][Full Text] [Related]
10. Nanovectorization of TRAIL with single wall carbon nanotubes enhances tumor cell killing.
Zakaria AB; Picaud F; Rattier T; Pudlo M; Dufour F; Saviot L; Chassagnon R; Lherminier J; Gharbi T; Micheau O; Herlem G
Nano Lett; 2015 Feb; 15(2):891-5. PubMed ID: 25584433
[TBL] [Abstract][Full Text] [Related]
11. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.
Gasparian ME; Chernyak BV; Dolgikh DA; Yagolovich AV; Popova EN; Sycheva AM; Moshkovskii SA; Kirpichnikov MP
Apoptosis; 2009 Jun; 14(6):778-87. PubMed ID: 19412666
[TBL] [Abstract][Full Text] [Related]
12. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
13. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
[TBL] [Abstract][Full Text] [Related]
14. Death receptor 5 is activated by fucosylation in colon cancer cells.
Zhang B; van Roosmalen IAM; Reis CR; Setroikromo R; Quax WJ
FEBS J; 2019 Feb; 286(3):555-571. PubMed ID: 30589515
[TBL] [Abstract][Full Text] [Related]
15. Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.
Gasparian ME; Bychkov ML; Yagolovich AV; Dolgikh DA; Kirpichnikov MP
Biochemistry (Mosc); 2015 Aug; 80(8):1080-91. PubMed ID: 26547077
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of antitumor properties of rhTRAIL by affinity increase toward its death receptors.
Reis CR; van der Sloot AM; Szegezdi E; Natoni A; Tur V; Cool RH; Samali A; Serrano L; Quax WJ
Biochemistry; 2009 Mar; 48(10):2180-91. PubMed ID: 19236007
[TBL] [Abstract][Full Text] [Related]
17. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5.
Lemke J; Noack A; Adam D; Tchikov V; Bertsch U; Röder C; Schütze S; Wajant H; Kalthoff H; Trauzold A
J Mol Med (Berl); 2010 Jul; 88(7):729-40. PubMed ID: 20354842
[TBL] [Abstract][Full Text] [Related]
18. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
Zhang Y; Zhang B
Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
[TBL] [Abstract][Full Text] [Related]
19. Repression of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but not its receptors during oral cancer progression.
Vigneswaran N; Baucum DC; Wu J; Lou Y; Bouquot J; Muller S; Zacharias W
BMC Cancer; 2007 Jun; 7():108. PubMed ID: 17592646
[TBL] [Abstract][Full Text] [Related]
20. DR4-Ser424
Lee H; Oh Y; Jeon YJ; Lee SY; Kim H; Lee HJ; Jung YK
Cancer Res; 2019 Jun; 79(11):2839-2852. PubMed ID: 30987996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
